Can I read Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial on EtoBox?

Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial by Ligang Xing; Gang Wu; Luhua Wang; Jiancheng Li; Jianhua Wang; Zhiyong Yuan; Ming Chen; Yaping Xu; Xiaolong Fu; Zhengfei Zhu; You Lu; Chun Han; Tingyi Xia; Conghua Xie; Guang Li; Shenglin Ma; Bing Lu; Qin Lin; Guangying Zhu; Baolin Qu; Wanqi Zhu; Jinming Yu is a Medicine article available to read on EtoBox.

What is Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial about?

## Purpose: This study aimed to compare erlotinib (e) and etoposide/cisplatin (ep) with concurrent radiation therapy (rt) for patients with stage iiia/b unresectable advanced non-small cell lung cancer with activating epidermal growth factor receptor mutation (egfrm+). ## Methods and patients: This was a multicenter, randomized, open-label, phase 2 trial conducted across 19 institutions in china (december 2012 to january 2016). enrolled patients were randomized (1:1) to e + rt (oral erlotinib 150 mg/d for 2 years or until disease progression or intolerable toxicity and rt 200 cgy/d, 5 d/wk for 6 weeks from the first day of erlotinib) or ep + rt (etoposide 50 mg/m intravenously on days 1-5 and 29-33; cisplatin 50 mg/m intravenously on days 1, 8, 29 and 36; and rt as for e + rt). the primary endpoint was progression-free survival (pfs). secondary endpoints included objective response rate and safety. ## Results: Two hundred fifty-two patients were screened, and 20 patients with egfrm+ in each group received the allocated e + rt or ep + rt treatment. patient characteristics were well balanced between groups. compared with ep + rt, median pfs with e + rt was significantly longer (24.5

Who reads Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial?

Author

Ligang Xing; Gang Wu; Luhua Wang; Jiancheng Li; Jianhua Wang; Zhiyong Yuan; Ming Chen; Yaping Xu; Xiaolong Fu; Zhengfei Zhu; You Lu; Chun Han; Tingyi Xia; Conghua Xie; Guang Li; Shenglin Ma; Bing Lu; Qin Lin; Guangying Zhu; Baolin Qu; Wanqi Zhu; Jinming Yu

Publisher

Elsevier BV

Published

2020

Language

EN

Field

Medicine (Health Sciences)